{"publication_id":"1a265041-dcba-4d47-9a2a-af0e73104267","traces":[{"claim_id":"claim_1","claim":"The direct receipts support a narrow working claim: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia‐free state (MLFS); Responses were observed in 4 (50%) of 8 RUNX1‐mutated patients. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.","candidate_sources":[{"study":"Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","doi":"10.1002/ajh.25000","url":null},{"study":"Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL","doi":"10.1200/jco.23.01075","url":null},{"study":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","doi":"10.1002/ajh.25978","url":null},{"study":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","doi":"10.1182/blood-2018-08-868752","url":null},{"study":"Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML","doi":"10.1182/blood-2024-204375","url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","doi":"10.1002/ajh.25000","url":null},{"study":"Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL","doi":"10.1200/jco.23.01075","url":null},{"study":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","doi":"10.1002/ajh.25978","url":null},{"study":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","doi":"10.1182/blood-2018-08-868752","url":null},{"study":"Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML","doi":"10.1182/blood-2024-204375","url":null}]},{"claim_id":"claim_3","claim":"Real tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.","candidate_sources":[{"study":"Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","doi":"10.1002/ajh.25000","url":null},{"study":"Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL","doi":"10.1200/jco.23.01075","url":null},{"study":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","doi":"10.1002/ajh.25978","url":null},{"study":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","doi":"10.1182/blood-2018-08-868752","url":null},{"study":"Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML","doi":"10.1182/blood-2024-204375","url":null}]},{"claim_id":"claim_4","claim":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._","candidate_sources":[{"study":"Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","doi":"10.1002/ajh.25000","url":null},{"study":"Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL","doi":"10.1200/jco.23.01075","url":null},{"study":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","doi":"10.1002/ajh.25978","url":null},{"study":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","doi":"10.1182/blood-2018-08-868752","url":null},{"study":"Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML","doi":"10.1182/blood-2024-204375","url":null}]},{"claim_id":"claim_5","claim":"`fact_id=90736` (`B_context`) — Significant increases in epigenetic age acceleration were observed in first-generation epigenetic clocks and mitotic clocks at 3 and 6 months doi=10.18632/aging.205581","candidate_sources":[{"study":"Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","doi":"10.1002/ajh.25000","url":null},{"study":"Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL","doi":"10.1200/jco.23.01075","url":null},{"study":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","doi":"10.1002/ajh.25978","url":null},{"study":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","doi":"10.1182/blood-2018-08-868752","url":null},{"study":"Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML","doi":"10.1182/blood-2024-204375","url":null}]},{"claim_id":"claim_6","claim":"`fact_id=164159` (`A_core`) — related mortality was not increased (2%) Source: A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","candidate_sources":[{"study":"Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","doi":"10.1002/ajh.25000","url":null},{"study":"Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL","doi":"10.1200/jco.23.01075","url":null},{"study":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","doi":"10.1002/ajh.25978","url":null},{"study":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","doi":"10.1182/blood-2018-08-868752","url":null},{"study":"Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML","doi":"10.1182/blood-2024-204375","url":null}]}]}